- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07491952
Kontinuerlig dobbeltaspirasjonsteknikk med Zoom-system for hjerneslag (ADAPT 2 0)
Klinisk evaluering av kontinuerlig dobbel aspirasjonsteknikk med Zoom-system for slag (ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Pojai Phattanagosai
- Telefonnummer: 650-740-7703
- E-post: pphattanagosai@Imperativecare.com
Studer Kontakt Backup
- Navn: Emma Pham
- Telefonnummer: 408-421-7684
- E-post: epham@imperativecare.com
Studiesteder
-
-
Alabama
-
Huntsville, Alabama, Forente stater, 35801
- Rekruttering
- Huntsville Hospital
-
Ta kontakt med:
- Farrar Hickey
-
Hovedetterforsker:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek, California, Forente stater, 94598
- Rekruttering
- John Muir Health
-
Hovedetterforsker:
- Benjamin Yim, MD
-
Ta kontakt med:
- Melenie Aaron
-
-
Florida
-
Tampa, Florida, Forente stater, 33606
- Rekruttering
- University of South Florida
-
Hovedetterforsker:
- Maxim Mokin, MD
-
Ta kontakt med:
- Kilaun Robinson
-
-
Georgia
-
Marietta, Georgia, Forente stater, 30060
- Rekruttering
- Wellstar Kennestone Hospital
-
Ta kontakt med:
- Autumn Lee
-
Hovedetterforsker:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette, Louisiana, Forente stater, 70503
- Rekruttering
- Ochsner Clinic Foundation (Lafayette)
-
Hovedetterforsker:
- Shail Thanki, MD
-
New Orleans, Louisiana, Forente stater, 70121
- Rekruttering
- Ochsner Clinic Foundation
-
Hovedetterforsker:
- James Milburn, MD
-
Ta kontakt med:
- Jessica Henry
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- Rekruttering
- University of Maryland
-
Hovedetterforsker:
- Jacob Cherian, MD
-
Ta kontakt med:
- Katie Henry
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55407
- Rekruttering
- Allina Health
-
Ta kontakt med:
- Emeryth Beloy
-
Hovedetterforsker:
- Collin Torok, MD
-
-
New York
-
Albany, New York, Forente stater, 12208
- Rekruttering
- Albany Medical College
-
Hovedetterforsker:
- Alexandra Paul, MD
-
Ta kontakt med:
- Chelsey Large
-
Buffalo, New York, Forente stater, 14203
- Rekruttering
- University at Buffalo Neurosurgery
-
Hovedetterforsker:
- Jason Davies, MD
-
Ta kontakt med:
- Ellen Carl
-
New York, New York, Forente stater, 10065
- Rekruttering
- Weill Cornell Medicine
-
Ta kontakt med:
- Hanah Hwang
-
Hovedetterforsker:
- Amol Mehta, MD
-
New York, New York, Forente stater, 10029
- Rekruttering
- Icahn School of Medicine at Mount Sinai
-
Ta kontakt med:
- Kevin Buttet
-
Hovedetterforsker:
- Michael T Caton, MD
-
Syracuse, New York, Forente stater, 13210
- Rekruttering
- SUNY Upstate Medical Center
-
Ta kontakt med:
- Saptarshi Prachi
-
Hovedetterforsker:
- Haydn Hoffman, MD
-
The Bronx, New York, Forente stater, 10467
- Rekruttering
- Montefiore Medical Center
-
Ta kontakt med:
- Genesis Liriano
-
Hovedetterforsker:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45220
- Rekruttering
- TriHealth Good Samaritan Hospital
-
Hovedetterforsker:
- Andrew Ringer, MD
-
Ta kontakt med:
- Mehnaaz Ali
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Rekruttering
- University of Oklahoma, Health Science Center
-
Hovedetterforsker:
- Hakeem Shakir, MD
-
Ta kontakt med:
- Sanaa Hameed
-
-
South Carolina
-
Greenville, South Carolina, Forente stater, 29605
- Rekruttering
- Prisma Health - Upstate
-
Ta kontakt med:
- Shawn Manos
-
Hovedetterforsker:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37902
- Rekruttering
- Fort Sanders Regional Medical Center
-
Ta kontakt med:
- Cameron Carter
-
Hovedetterforsker:
- Robert Hixson, MD
-
Memphis, Tennessee, Forente stater, 38120
- Rekruttering
- Semmes Murphey Foundation
-
Hovedetterforsker:
- Lucas Elijovich, MD
-
Ta kontakt med:
- Wendell Barnett
-
-
Texas
-
Kingwood, Texas, Forente stater, 77339
- Rekruttering
- HCA Houston Healthcare Kingwood
-
Hovedetterforsker:
- Mohamad Ezzeldin, MD
-
Ta kontakt med:
- Swathi Potla
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Methodist Healthcare System of San Antonio
-
Ta kontakt med:
- Samantha Franklin
-
Hovedetterforsker:
- Lee Birnbaum, MD
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- University of Texas Science Health Center at San Antonio
-
Hovedetterforsker:
- Justin Mascitelli, MD
-
Ta kontakt med:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Rekruttering
- University of Utah
-
Ta kontakt med:
- Andrew Grandemange
-
Hovedetterforsker:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church, Virginia, Forente stater, 22042
- Rekruttering
- Inova Fairfax Medical Campus
-
Ta kontakt med:
- Lauren Monroe
-
Hovedetterforsker:
- James McEachern, MD
-
-
Washington
-
Spokane, Washington, Forente stater, 99204
- Rekruttering
- Providence Sacred Heart Medical Center and Children's Hospital
-
Ta kontakt med:
- Kyle Kramer
-
Hovedetterforsker:
- Christopher Zylak, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
Beskrivelse
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Tidsramme: End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Tidsramme: End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Tidsramme: Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Tidsramme: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Tidsramme: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
Tidsramme: Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
Tidsramme: 90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Tidsramme: Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Tidsramme: 24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
Tidsramme: 90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Tidsramme: Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: David Fiorella, MD, Stony Brook University Hospital
- Hovedetterforsker: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
- Hovedetterforsker: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
- Hovedetterforsker: Maxim Mokin, MD, University of South Florida
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ICI-2025-003
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .